Global Markets for Drug-Device Combinations
The market for global drug device combination products was valued at $18.5 billion in 2011 and should reach $19 billion in 2012. Total market value is expected to reach $30.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.9%.
- An overview of the global market for drug-device combinations
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Detailed coverage of such product categories as drug-eluting stents (DES), drug-eluting beads (DEB), antimicrobial catheters, antibiotic-loaded bone cements, glass ionomer cements, bone graft substitutes, antibacterial-releasing dental-restorative materials, biologic wound-care products such as collagen-based dressings as therapeutic agents for wound-healing, drug-device combination products for ocular applications, and photodynamic therapy
- Identification of current and future technologies, products, market segments/end markets, and government and regulatory agencies
- Discussion of participating companies in light of technological strengths and weaknesses, relative market shares, marketing strengths, and innovative marketing practices
- Detailed patent analysis and research and development updates
- Comprehensive company profiles of major players.
SCOPE AND FORMAT
In preparing this report, an overall study of the drug-device combination market was undertaken.
The report covers the following product categories:
- Drug-eluting stents (DES).
- Drug-eluting beads (DEB).
- Transdermal patches.
- Antimicrobial catheters.
- Antibiotic-loaded bone cements.
- Glass ionomer cements.
- Bone graft substitutes.
- Antibacterial-releasing dental restorative materials.
- Biologic wound care products, such as collagen-based dressings as therapeutic agents for wound healing.
- Drug-device combination products for ocular applications.
- Photodynamic therapy.
- Many nanotechnology applications.
Devices that do not combine a drug with the delivery mechanism are not covered; for example, insulin pumps are not covered.
Related areas, such as drug delivery systems and nanotechnology, were key to the analysis as well, as these newer areas such as nanotechnology foreshadow likely product developments in the years ahead. All major aspects of the drug-device combination market are addressed including identification of current and future technologies, products, market segments/end markets, and government and regulatory involvement. Participating companies are discussed in light of technological strengths and weakness, relative market share, marketing strengths, and innovative marketing practices. Included is a detailed discussion of the current regulatory environment for drug-device combination products and how it is affecting development and approval of such products.
Research analyst Kevin Gainer holds both B.A. and M.A. degrees in quantitative economic analysis and forecasting, and has 26 years of economic forecasting, industry intelligence and market research experience. He is the author of six published books and more than 100 magazine articles, technical papers, analyses, and studies published in conference proceedings, including many unpublished within corporations. He has worked as a Research Editor and Project Analyst at BCC Research since 1985, and has authored numerous BCC technology market research reports.
- Overall sales of drug device combination products were $12 billion in 2008 and $13.7 billion in 2009. This is projected to reach $27 billion in 2014 at a compound annual growth rate (CAGR) of 14.5%
- Sales in coronary stents Products were nearly $4.4 billion in 2008 and $4.8 billion in 2009. This market is projected to reach $7.4 billion in 2014, for a 5-year CAGR of 9%.
- Photodynamic therapies market was $1.3 billion in 2008, which increased slightly in 2009 to $1.5 billion. This market is projected to reach approx $2.6 billion in 2014, for a 5-year CAGR of 11.6%.
The total market for drug-device combinations worldwide was valued at $5.4 billion in 2004 and is expected to rise at an average annual growth rate (AAGR) of 13.6% to $11.5 billion in 2010.
The star category is drug-eluting stents that will continue to show average annual growth of 11.5%. This will result in the market doubling to $8 billion in 2010.
With the exception of bone graft substitutes and antibiotic bone cements, all categories will show double-digit growth.
The U.S. dominates the market for drug-device combination products, mainly because the largest-selling drug-eluting stents have been enthusiastically accepted in this market and consequently are penetrating the market more quickly than in Europe.